Jason Kelly, Ginkgo Bioworks CEO (Adam Glanzman/Bloomberg via Getty Images)

Ex­clu­sive: Pfiz­er, Gink­go sign R&D deal worth up to $331M to de­vel­op RNA drugs

In its lat­est Big Phar­ma deal, Gink­go Bioworks will work with Pfiz­er to de­vel­op new RNA drugs, the Boston-based syn­thet­ic bi­ol­o­gy start­up ex­clu­sive­ly told End­points News.

The two aren’t dis­clos­ing many specifics about the col­lab­o­ra­tion, but the deal will fo­cus on three RNA ther­a­peu­tic pro­grams, out­lin­ing $331 mil­lion in po­ten­tial mile­stone pay­ments, in­clud­ing an undis­closed amount up­front. Gink­go CEO Ja­son Kel­ly said it’s the lat­est ex­am­ple of ther­a­peu­tics be­ing the fastest-grow­ing area of Gink­go’s busi­ness.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.